BR112012013582A2 - processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos - Google Patents

processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos

Info

Publication number
BR112012013582A2
BR112012013582A2 BR112012013582A BR112012013582A BR112012013582A2 BR 112012013582 A2 BR112012013582 A2 BR 112012013582A2 BR 112012013582 A BR112012013582 A BR 112012013582A BR 112012013582 A BR112012013582 A BR 112012013582A BR 112012013582 A2 BR112012013582 A2 BR 112012013582A2
Authority
BR
Brazil
Prior art keywords
production
synthesis
substituted indazole
compounds
intermediates useful
Prior art date
Application number
BR112012013582A
Other languages
English (en)
Portuguese (pt)
Inventor
Hossein Razavi
Jonathan Timothy Reeves
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112012013582A2 publication Critical patent/BR112012013582A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012013582A 2009-12-08 2010-12-01 processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos BR112012013582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08
PCT/US2010/058594 WO2011071730A1 (en) 2009-12-08 2010-12-01 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Publications (1)

Publication Number Publication Date
BR112012013582A2 true BR112012013582A2 (pt) 2016-07-05

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013582A BR112012013582A2 (pt) 2009-12-08 2010-12-01 processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos

Country Status (17)

Country Link
US (1) US20110137042A1 (enExample)
EP (1) EP2509952A1 (enExample)
JP (1) JP2013512954A (enExample)
KR (1) KR20120101667A (enExample)
CN (1) CN102596908A (enExample)
AR (1) AR079324A1 (enExample)
AU (1) AU2010328480A1 (enExample)
BR (1) BR112012013582A2 (enExample)
CA (1) CA2782384A1 (enExample)
CL (1) CL2012001300A1 (enExample)
EA (1) EA201200820A1 (enExample)
IL (1) IL219274A0 (enExample)
IN (1) IN2012DN05081A (enExample)
MX (1) MX2012006524A (enExample)
PH (1) PH12012501153A1 (enExample)
TW (1) TW201144282A (enExample)
WO (1) WO2011071730A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
PE20121433A1 (es) 2009-10-21 2012-11-10 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2116863A1 (en) * 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
KR950702555A (ko) * 1993-06-25 1995-07-29 모치츠키 노부히코 인다졸술포닐요소 유도체, 그의 용도 및 제조 중간체(indazolesulfonylurea derivative, its use and intermediate for its production)
CA2207201A1 (en) * 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
ES2248084T3 (es) * 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60235114D1 (de) * 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
ZA200507284B (en) * 2003-03-12 2007-03-28 Celgene Corp 7-amino-isoindolyl compounds and their pharmaceutical uses
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2007502307A (ja) * 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ(muri)の阻害剤としての縮合複素環
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
DK1860941T3 (da) * 2005-03-16 2009-03-02 Basf Se Biphenyl-N-(4-pyridyl)methylsufonamider
PL2444079T3 (pl) * 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
BRPI0615048A2 (pt) * 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
WO2007102883A2 (en) * 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
US8097617B2 (en) * 2006-03-31 2012-01-17 Novartis Ag Organic compounds
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びp2x7受容体阻害剤
WO2009134666A1 (en) * 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1

Also Published As

Publication number Publication date
AR079324A1 (es) 2012-01-18
MX2012006524A (es) 2012-07-17
EP2509952A1 (en) 2012-10-17
TW201144282A (en) 2011-12-16
AU2010328480A1 (en) 2012-05-17
IN2012DN05081A (enExample) 2015-10-09
CN102596908A (zh) 2012-07-18
CA2782384A1 (en) 2011-06-16
CL2012001300A1 (es) 2012-09-07
IL219274A0 (en) 2012-06-28
JP2013512954A (ja) 2013-04-18
PH12012501153A1 (en) 2012-10-22
KR20120101667A (ko) 2012-09-14
US20110137042A1 (en) 2011-06-09
EA201200820A1 (ru) 2013-01-30
WO2011071730A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
UY33256A (es) Procedimiento de sintesis de derivados de cetobenzofurano
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
MX350892B (es) Síntesis de compuesto antiviral.
BR112012013582A2 (pt) processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
JO2816B1 (en) A new process for the installation of agililatine
BR112013001245A2 (pt) método de produção de ingenol-3-angelato
JO2818B1 (en) A new process for the installation of agililatine
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
IN2014DN00144A (enExample)
NZ586187A (en) Processes for the synthesis of sinomenine derivatives and their intermediate
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
SV2009003153A (es) Bencilaminas, un proceso para su produccion y su uso como agentes antiinflamatorios
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
MX2012001411A (es) Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico.
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
UY31577A1 (es) Proceso para la preparacion de 6-sustituido-1-(2h)-isoquinolinonas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]